Motesanib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Motesanib
Accession Number
DB05575
Description
Not Available
Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 373.4509
Monoisotopic: 373.190260383
Chemical Formula
C22H23N5O
Synonyms
  • Motesanib
External IDs
  • AMG 706
  • AMG-706

Pharmacology

Indication

Investigated for use/treatment in solid tumors.

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbaloparatideThe therapeutic efficacy of Abaloparatide can be decreased when used in combination with Motesanib.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Motesanib.
CarbimazoleThe therapeutic efficacy of Carbimazole can be decreased when used in combination with Motesanib.
FollitropinThe therapeutic efficacy of Follitropin can be decreased when used in combination with Motesanib.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Motesanib.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Motesanib.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Motesanib.
MethimazoleThe therapeutic efficacy of Methimazole can be decreased when used in combination with Motesanib.
Parathyroid hormoneThe therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Motesanib.
Potassium IodideThe therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Motesanib.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Product Ingredients
IngredientUNIICASInChI Key
Motesanib diphosphateT6Q3060U91857876-30-3ONDPWWDPQDCQNJ-UHFFFAOYSA-N

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as indolines. These are compounds containing an indole moiety, which consists of pyrrolidine ring fused to benzene to form 2,3-dihydroindole.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indolines
Direct Parent
Indolines
Alternative Parents
Nicotinamides / Secondary alkylarylamines / Aralkylamines / Aminopyridines and derivatives / Imidolactams / Benzenoids / Vinylogous amides / Heteroaromatic compounds / Secondary carboxylic acid amides / Amino acids and derivatives
show 5 more
Substituents
Amine / Amino acid or derivatives / Aminopyridine / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Carboxamide group / Carboxylic acid derivative / Dihydroindole
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
pyridinecarboxamide (CHEBI:51098)

Chemical Identifiers

UNII
U1JK633AYI
CAS number
453562-69-1
InChI Key
RAHBGWKEPAQNFF-UHFFFAOYSA-N
InChI
InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28)
IUPAC Name
N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-{[(pyridin-4-yl)methyl]amino}pyridine-3-carboxamide
SMILES
CC1(C)CNC2=CC(NC(=O)C3=C(NCC4=CC=NC=C4)N=CC=C3)=CC=C12

References

General References
Not Available
ChemSpider
9842625
BindingDB
24773
ChEBI
51098
ChEMBL
CHEMBL572881
ZINC
ZINC000018710082
PharmGKB
PA166118340
PDBe Ligand
706
Wikipedia
Motesanib
PDB Entries
3efl

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)2
2CompletedTreatmentAdvanced Gastrointestinal Stromal Tumors1
2CompletedTreatmentCarcinoid tumour of the gastrointestinal tract / Islet Cell Tumor / Neoplastic Syndrome1
2CompletedTreatmentFallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Cavity Cancer1
2CompletedTreatmentGastrointestinal Cancers1
2CompletedTreatmentThyroid Cancers1
2TerminatedTreatmentAdvanced Non-squamous NSCLC1
2TerminatedTreatmentBreast Cancer / Locally Recurrent and Metastatic Breast Cancer / Neoplasms, Breast / Tumors, Breast1
2TerminatedTreatmentTumors, Solid1
1CompletedDiagnosticAdvanced Solid Tumors1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0112 mg/mLALOGPS
logP3.59ALOGPS
logP3.33ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)15.56ChemAxon
pKa (Strongest Basic)5.43ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area78.94 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity114.77 m3·mol-1ChemAxon
Polarizability40.66 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on November 18, 2007 11:26 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates